BGB-11417-303/CLL-RR1 / A Phase 3 Randomized Open-Label Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Learn More About This Study
